MCID: END041
MIFTS: 63

Endometrial Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Adenocarcinoma

MalaCards integrated aliases for Endometrial Adenocarcinoma:

Name: Endometrial Adenocarcinoma 12 15 71
Endometrial Endometrioid Adenocarcinoma 12 17 71
Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation 6 17
Endometrial Adenoacanthoma 12 71
Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation 12
Endometrioid Carcinoma of Endometrium 12
Endometrioid Adenomas and Carcinomas 12
Adenocarcinoma of the Endometrium 12
Endometrioid Adenoma or Carcinoma 12
Adenocarcinoma of Endometrium 12
Endometrium Adenocarcinoma 17
Adenocarcinoma of Uterus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2870
SNOMED-CT 67 309245001 762458004
UMLS 71 C0279763 C1153706 C1336905

Summaries for Endometrial Adenocarcinoma

Disease Ontology : 12 An endometrial carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Endometrial Adenocarcinoma, also known as endometrial endometrioid adenocarcinoma, is related to endometrial mucinous adenocarcinoma and endometrial hyperplasia. An important gene associated with Endometrial Adenocarcinoma is FGFR2 (Fibroblast Growth Factor Receptor 2), and among its related pathways/superpathways are Gene Expression and ERK Signaling. The drugs Dexmedetomidine and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Endometrial Adenocarcinoma

Diseases related to Endometrial Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 624)
# Related Disease Score Top Affiliating Genes
1 endometrial mucinous adenocarcinoma 32.9 PGR CDKN2A
2 endometrial hyperplasia 31.1 VEGFA TP53 PTEN PGR MLH1 KRAS
3 adenomyosis 31.0 VEGFA TP53 PGR ESR2 ESR1 CDH1
4 estrogen excess 31.0 PTEN PGR ESR2 ESR1
5 neuroendocrine carcinoma 30.9 PTEN KRT7 CDH1
6 cystadenoma 30.9 PTEN PGR KRT7
7 endocervical adenocarcinoma 30.8 TP53 PGR KRT7 ESR1 ERBB2 CDKN2A
8 adenomyoma 30.7 PGR MLH1 KRT7 ESR1 CDKN2A
9 endometrial serous adenocarcinoma 30.7 TP53 PTEN PGR KRAS ERBB2
10 leiomyosarcoma 30.7 VEGFA TP53 PGR ESR1 CDKN2A
11 large cell neuroendocrine carcinoma 30.7 KRT7 ERBB2 EGFR
12 adenosquamous carcinoma 30.7 TP53 PTEN PGR KRT7 KRAS EGFR
13 appendix adenocarcinoma 30.7 KRT7 KRAS
14 bizarre leiomyoma 30.6 TP53 PGR ESR1 CDKN2A
15 adenocarcinoma in situ 30.6 KRT7 KRAS EGFR CDKN2A
16 ovarian clear cell adenocarcinoma 30.5 TP53 PGR ESR2
17 cystic teratoma 30.5 TP53 PTEN KRT7 KRAS CDKN2A
18 papillary adenocarcinoma 30.5 TP53 PGR KRT7 KRAS ERBB2 CDH1
19 intravenous leiomyomatosis 30.5 PGR ESR1
20 endosalpingiosis 30.5 TP53 PGR KRT7 KRAS
21 adenosarcoma 30.5 TP53 PGR ESR1 ERBB2
22 endometriosis of ovary 30.5 PTEN PGR ESR2 ESR1
23 adenoma 30.5 TP53 MLH1 KRT7 KRAS CDKN2A CDH1
24 papillary serous adenocarcinoma 30.5 TP53 PGR KRT7 KRAS
25 endometrioid ovary carcinoma 30.4 TP53 PTEN MLH1 KRAS
26 appendiceal neoplasm 30.4 KRT7 KRAS
27 peutz-jeghers syndrome 30.4 TP53 PTEN EGFR
28 papillary carcinoma 30.4 PGR KRT7 ESR1 ERBB2 CDH1
29 teratoma 30.4 TP53 PTEN KRT7 KRAS ESR1 CDKN2A
30 mature teratoma 30.4 TP53 KRT7 KRAS ERBB2
31 pleomorphic adenoma 30.3 TP53 KRT7 ERBB2 CDKN2A
32 cystitis 30.3 VEGFA TP53 KRT7 CDH1
33 rhabdomyosarcoma 30.3 VEGFA TP53 PTEN KRAS EGFR CDKN2A
34 pseudomyxoma peritonei 30.3 TP53 KRT7 KRAS CDH1
35 endometriosis 30.3 VEGFA TP53 PTEN PGR MIR200A ESR2
36 carcinosarcoma 30.3 TP53 PTEN PGR KRT7 KRAS ERBB2
37 squamous cell papilloma 30.3 TP53 CDKN2A
38 cervical adenocarcinoma 30.3 TP53 PTEN PGR KRT7 KRAS ESR1
39 fallopian tube carcinoma 30.2 VEGFA TP53 PTEN PGR ESR1 ERBB2
40 adenocarcinoma 30.2 VEGFA TP53 PTEN MLH1 MALAT1 KRT7
41 lynch syndrome 30.2 TP53 PTEN MLH1 KRAS ERBB2 EGFR
42 hemangioma 30.1 VEGFA TP53 PTEN PGR KRT7 KRAS
43 bilateral breast cancer 30.1 PTEN PGR MLH1 ESR1 ERBB2 CDKN2A
44 cervical squamous cell carcinoma 30.1 VEGFA TP53 MLH1 KRAS EGFR CDKN2A
45 ovarian clear cell carcinoma 30.1 VEGFA TP53 PTEN MLH1 KRT7 KRAS
46 female reproductive endometrioid cancer 30.0 TP53 PTEN PGR MLH1 KRAS ESR1
47 signet ring cell adenocarcinoma 30.0 TP53 MLH1 KRT7 KRAS ERBB2 CDH1
48 tubular adenocarcinoma 30.0 PGR KRT7 ESR1 ERBB2 EGFR CDH1
49 papilloma 29.9 VEGFA TP53 PTEN KRT7 KRAS ESR1
50 pheochromocytoma 29.9 VEGFA KRT7 ESR1 ERBB2 CDKN2A CDH1

Graphical network of the top 20 diseases related to Endometrial Adenocarcinoma:



Diseases related to Endometrial Adenocarcinoma

Symptoms & Phenotypes for Endometrial Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.68 EGFR KRAS
2 Decreased viability GR00055-A-2 9.68 EGFR KRAS
3 Decreased viability GR00055-A-3 9.68 KRAS
4 Decreased viability GR00106-A-0 9.68 KRAS
5 Decreased viability GR00221-A-1 9.68 CDH1 CDKN2A EGFR ESR1 KRAS
6 Decreased viability GR00221-A-2 9.68 ESR1 KRAS
7 Decreased viability GR00221-A-3 9.68 CDKN2A
8 Decreased viability GR00221-A-4 9.68 CDKN2A EGFR ESR1
9 Decreased viability GR00301-A 9.68 CDH1 KRAS
10 Decreased viability GR00381-A-1 9.68 KRAS
11 Decreased viability GR00386-A-1 9.68 ESR1
12 Decreased viability GR00402-S-2 9.68 CDH1 ESR1

MGI Mouse Phenotypes related to Endometrial Adenocarcinoma:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
2 homeostasis/metabolism MP:0005376 10.41 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
3 cardiovascular system MP:0005385 10.38 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
4 endocrine/exocrine gland MP:0005379 10.38 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
5 digestive/alimentary MP:0005381 10.36 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
6 growth/size/body region MP:0005378 10.34 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
7 immune system MP:0005387 10.34 CDH1 CDKN2A EGFR ESR1 ESR2 FGFR2
8 embryo MP:0005380 10.32 CDH1 CDKN2A EGFR ERBB2 ESR1 FGFR2
9 integument MP:0010771 10.32 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
10 hematopoietic system MP:0005397 10.29 CDKN2A EGFR ESR1 ESR2 FGFR2 KRAS
11 neoplasm MP:0002006 10.25 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
12 muscle MP:0005369 10.2 CDKN2A EGFR ERBB2 ESR1 ESR2 FGFR2
13 limbs/digits/tail MP:0005371 10.19 EGFR ERBB2 ESR1 ESR2 FGFR2 KRAS
14 liver/biliary system MP:0005370 10.13 CDKN2A EGFR ESR1 ESR2 FGFR2 KRAS
15 normal MP:0002873 10.11 CDH1 EGFR ERBB2 ESR1 ESR2 FGFR2
16 no phenotypic analysis MP:0003012 10.1 CDH1 CDKN2A EGFR ESR1 ESR2 FGFR2
17 reproductive system MP:0005389 9.97 CDH1 CDKN2A EGFR ERBB2 ESR1 ESR2
18 renal/urinary system MP:0005367 9.91 EGFR ESR1 ESR2 FGFR2 KRAS KRT7
19 pigmentation MP:0001186 9.8 CDKN2A EGFR FGFR2 KRAS PTEN TP53
20 respiratory system MP:0005388 9.7 CDKN2A EGFR ERBB2 ESR1 ESR2 FGFR2
21 skeleton MP:0005390 9.36 CDKN2A EGFR ERBB2 ESR1 ESR2 FGFR2

Drugs & Therapeutics for Endometrial Adenocarcinoma

Drugs for Endometrial Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
4 Adrenergic alpha-Agonists Phase 4
5 Excitatory Amino Acid Antagonists Phase 4
6 Hypnotics and Sedatives Phase 4
7 Anesthetics, Dissociative Phase 4
8 Adrenergic Agents Phase 4
9 Analgesics Phase 4
10 Adrenergic Agonists Phase 4
11 Anesthetics, General Phase 4
12 Anesthetics, Intravenous Phase 4
13 Analgesics, Non-Narcotic Phase 4
14 Anesthetics, Local Phase 4
15 Anesthetics Phase 4
16 Neurotransmitter Agents Phase 4
17
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
18
Lenograstim Approved, Investigational Phase 3 135968-09-1
19
Epirubicin Approved Phase 3 56420-45-2 41867
20
Pembrolizumab Approved Phase 3 1374853-91-4
21
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
22
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
23
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
24
Liposomal doxorubicin Phase 3 31703
25 Adjuvants, Immunologic Phase 3
26 Albumin-Bound Paclitaxel Phase 2, Phase 3
27 Tubulin Modulators Phase 2, Phase 3
28 Antimitotic Agents Phase 2, Phase 3
29 Hypoglycemic Agents Phase 2, Phase 3
30 Hormone Antagonists Phase 3
31 Hormones Phase 3
32 Estrogens Phase 3
33 Estrogens, Conjugated (USP) Phase 3
34
Gemcitabine Approved Phase 2 95058-81-4 60750
35
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
36
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
37
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
38
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
39
Nintedanib Approved Phase 2 656247-17-5 56843413
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
42
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
43
nivolumab Approved Phase 2 946414-94-4
44
Anastrozole Approved, Investigational Phase 1, Phase 2 120511-73-1 2187
45
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
46
Levonorgestrel Approved, Investigational Phase 2 797-63-7, 17489-40-6 13109
47
Acetaminophen Approved Phase 2 103-90-2 1983
48
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
2 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
3 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
4 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
5 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
7 A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Recruiting NCT04214067 Phase 3
8 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
9 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
10 A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma Terminated NCT00002976 Phase 3 conjugated estrogens
11 The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
12 Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer Unknown status NCT02990728 Phase 2 Metformin
13 Treatment With Medroxyprogesterone Acetate(MPA) Plus Levonorgestrel-releasing Intrauterine System(LNG-IUS) in Young Women With Early Stage Endometrial Cancer: Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2009) Unknown status NCT01594879 Phase 2
14 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
15 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed NCT01877564 Phase 2 Metformin
16 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
17 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT02697591 Phase 1, Phase 2 INCAGN01876
18 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT02923349 Phase 1, Phase 2 INCAGN01949
19 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
20 A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00095979 Phase 2 ixabepilone
21 A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma Completed NCT00087100 Phase 2 pemetrexed disodium
22 A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy Completed NCT00006089 Phase 2
23 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Completed NCT01968317 Phase 2 Megestrol acetate and metformin;Megestrol acetate
24 Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma. Completed NCT03540407 Phase 2
25 Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
26 Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer Completed NCT00870337 Phase 2 everolimus
27 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
28 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
29 A Phase II Study of Letrozole in Patients With Advanced or Recurrent Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
30 A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium Completed NCT00030485 Phase 2 erlotinib hydrochloride
31 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
32 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
33 A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
34 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
35 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
36 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
37 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
38 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
39 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
40 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
41 A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation for Stage III/IV Endometrial Carcinoma Completed NCT00285415 Phase 2 Docetaxel and Carboplatin
42 A Phase II Study of Combination Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium Completed NCT00584857 Phase 2 Paclitaxel ,Carboplatin , Megesterol Acetate
43 Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium Recruiting NCT03643510 Phase 2 Fulvestrant;Abemaciclib
44 A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer Recruiting NCT02684227 Phase 2 Carboplatin;Enzalutamide;Paclitaxel
45 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
46 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Recruiting NCT00492778 Phase 2 Cisplatin
47 Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma Recruiting NCT02549209 Phase 2 Pembrolizumab;Paclitaxel;Carboplatin
48 A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma Recruiting NCT02730923 Phase 1, Phase 2 AZD2014;Anastrozole
49 A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium Active, not recruiting NCT01686126 Phase 2 Levonorgestrel;Metformin
50 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Active, not recruiting NCT02728258 Phase 2 Copanlisib

Search NIH Clinical Center for Endometrial Adenocarcinoma

Genetic Tests for Endometrial Adenocarcinoma

Anatomical Context for Endometrial Adenocarcinoma

MalaCards organs/tissues related to Endometrial Adenocarcinoma:

40
Uterus, Lymph Node, Breast, Ovary, Cervix, Testes, Endothelial

Publications for Endometrial Adenocarcinoma

Articles related to Endometrial Adenocarcinoma:

(show top 50) (show all 2902)
# Title Authors PMID Year
1
Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. 46
19077565 2009
2
Does cervicovaginal cytology have a role in the diagnosis and surveillance of endometrial adenocarcinoma? 61
32333730 2020
3
Synchronous Well-differentiated Endometrioid Adenocarcinoma and Leiomyosarcoma of the Uterus With Pulmonary Metastasis in a 50-Yr-Old Woman: A Case Report and Review of Literature. 61
31157684 2020
4
Prediction of tumor grade and lymphovascular space invasion in endometrial adenocarcinoma with MR imaging-based radiomic analysis. 61
32037289 2020
5
Uterine disorders affecting female fertility: what are the molecular functions altered in endometrium? 61
32482256 2020
6
Expression of poly-ADP-ribose polymerase (PARP) in endometrial adenocarcinoma: Prognostic potential. 61
32360251 2020
7
Undifferentiated Endometrial Carcinoma Arising in the Background of High-Grade Endometrial Carcinoma - Expanding the Definition of Dedifferentiated Endometrial Carcinoma. 61
32557836 2020
8
miR-544a Stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs. 61
32525042 2020
9
Computer-Aided Diagnosis in Histopathological Images of the Endometrium Using a Convolutional Neural Network and Attention Mechanisms. 61
31581102 2020
10
Endometrial adenocarcinoma metastatic to the pituitary gland: a case report and literature review. 61
32500767 2020
11
Possibility of Targeting Claudin-2 in Therapy for Human Endometrioid Endometrial Carcinoma. 61
32548807 2020
12
ZEB1 modulates endometrial receptivity through epithelial-mesenchymal transition in endometrial epithelial cells in vitro. 61
32139122 2020
13
Anti-Adhesion Behavior from Ring-Strain Amine Cyclic Monolayers Grafted on Silicon (111) Surfaces. 61
32472042 2020
14
Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin. 61
32258333 2020
15
Effects of Vitamin D Analogs Alfacalcidol and Calcitriol on Cell Proliferation and Migration of HEC1A Endometrial Adenocarcinoma Cells. 61
32400204 2020
16
Adjusting to the new reality: Evaluation of early practice pattern adaptations to the COVID-19 pandemic. 61
32482336 2020
17
Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma. 61
32433831 2020
18
BMI‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor. 61
32323819 2020
19
Prognostic Role of Krüppel-Like Factors 5, 9, and 11 in Endometrial Endometrioid Cancer. 61
32451988 2020
20
Stigmasterol Causes Ovarian Cancer Cell Apoptosis by Inducing Endoplasmic Reticulum and Mitochondrial Dysfunction. 61
32481565 2020
21
Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system. 61
32489979 2020
22
Long non-coding RNA CCAT1 is overexpressed in endometrial cancer and regulates growth and transcriptome of endometrial adenocarcinoma cells. 61
32173521 2020
23
Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression. 61
30789355 2020
24
Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma. 61
31927619 2020
25
Endometrial adenocarcinoma arising in a pelvic implant following uterine morcellation: A case report. 61
32195127 2020
26
Endometrial Gastric (Gastrointestinal)-type Mucinous Lesions: Report of a Series Illustrating the Spectrum of Benign and Malignant Lesions. 61
31567280 2020
27
Primary tumor types and origins in positive abdominopelvic washing cytology, a single institution experience. 61
31734259 2020
28
Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia. 61
32124398 2020
29
Metastatic invasive lobular carcinoma of the breast to the endometrium presenting with abnormal uterine bleeding; Case report. 61
32071717 2020
30
Cholestatic Hepatitis as a Possible Paraneoplastic Syndrome of Endometrial Carcinoma. 61
32337313 2020
31
Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer. 61
31783169 2020
32
Does a history of malignancy impact the survival of a subsequent endometrial adenocarcinoma? Should clinical trials eligibility criteria be revisited? 61
31352852 2020
33
Papillary Cystadenofibroma of Fallopian Tube: Case Report with a Literature Review. 61
32317841 2020
34
Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique. 61
31783195 2020
35
Invasive endometrial adenocarcinoma and missed abortion: A case report. 61
31989012 2020
36
Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus. 61
31560127 2020
37
Two Distinct Tumorigenic Processes in Endometrial Endometrioid Adenocarcinoma. 61
31733184 2020
38
A case of three rare uterine neoplasms in the same surgical specimen. 61
32129176 2020
39
Prognostic significance of solid growth in endometrioid endometrial adenocarcinoma. 61
31452018 2020
40
Nine glycolysis-related gene signature predicting the survival of patients with endometrial adenocarcinoma. 61
32489319 2020
41
The Significance of Galectin-1 and Galectin-9 Expression in Endometrial Carcinoma. 61
31487707 2020
42
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. 61
31765263 2020
43
Robotic Colostomy Takedown in a Patient with Extensive Ventral Hernias and Adhesive Disease. 61
31838277 2019
44
Expression Profiles of the Phosphatase and Tensin Homolog (PTEN), CDH1, and CDH2 Genes, and the Cell Membrane Protein, CD133, in the Ishikawa Human Endometrial Adenocarcinoma Cell Line. 61
31864232 2019
45
Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides. 61
30362387 2019
46
Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. 61
31655172 2019
47
Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. 61
31373248 2019
48
Isolated acrometastasis: A rare presenting feature of endometrial carcinoma. 61
31898681 2019
49
Peritoneal Keratin Granulomatosis Is a Clinical and Radiological Mimicker of Endometrial Adenocarcinoma With Peritoneal Involvement. 61
31113276 2019
50
Synchronous benign Brenner's tumor of ovary with leiomyoma and endometrial adenocarcinoma in a postmenopausal female. 61
31898686 2019

Variations for Endometrial Adenocarcinoma

ClinVar genetic disease variations for Endometrial Adenocarcinoma:

6 (show all 18) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp)SNV Pathogenic 13272 rs79184941 10:123279677-123279677 10:121520163-121520163
2 FGFR2 NM_000141.5(FGFR2):c.1694A>G (p.Glu565Gly)SNV Likely pathogenic 374823 rs121918506 10:123256215-123256215 10:121496701-121496701
3 FGFR2 NM_000141.5(FGFR2):c.1645A>C (p.Asn549His)SNV Likely pathogenic 374821 rs1057519045 10:123258036-123258036 10:121498522-121498522
4 EGFR NM_005228.5(EGFR):c.2068G>A (p.Glu690Lys)SNV Likely pathogenic 376152 rs1057519794 7:55241620-55241620 7:55173927-55173927
5 FGFR2 NM_000141.5(FGFR2):c.1975A>G (p.Lys659Glu)SNV Likely pathogenic 376153 rs1057519795 10:123247516-123247516 10:121488002-121488002
6 FGFR2 NM_000141.5(FGFR2):c.1849T>A (p.Leu617Met)SNV Likely pathogenic 376154 rs1057519796 10:123256060-123256060 10:121496546-121496546
7 FGFR2 NM_000141.5(FGFR2):c.1690G>A (p.Val564Ile)SNV Likely pathogenic 376155 rs1057519797 10:123256219-123256219 10:121496705-121496705
8 FGFR2 NM_000141.5(FGFR2):c.1647T>G (p.Asn549Lys)SNV Likely pathogenic 376156 rs121913476 10:123258034-123258034 10:121498520-121498520
9 FGFR2 NM_000141.5(FGFR2):c.1647T>A (p.Asn549Lys)SNV Likely pathogenic 376157 rs121913476 10:123258034-123258034 10:121498520-121498520
10 FGFR2 NM_000141.5(FGFR2):c.1639A>G (p.Ile547Val)SNV Likely pathogenic 376158 rs1057519798 10:123258042-123258042 10:121498528-121498528
11 FGFR2 NM_000141.5(FGFR2):c.1611G>T (p.Met537Ile)SNV Likely pathogenic 376159 rs1057519799 10:123258070-123258070 10:121498556-121498556
12 FGFR2 NM_000141.5(FGFR2):c.1611G>C (p.Met537Ile)SNV Likely pathogenic 376160 rs1057519799 10:123258070-123258070 10:121498556-121498556
13 FGFR2 NM_000141.5(FGFR2):c.1611G>A (p.Met537Ile)SNV Likely pathogenic 376161 rs1057519799 10:123258070-123258070 10:121498556-121498556
14 FGFR2 NM_000141.5(FGFR2):c.1605G>T (p.Met535Ile)SNV Likely pathogenic 376162 rs1057519800 10:123258076-123258076 10:121498562-121498562
15 FGFR2 NM_000141.5(FGFR2):c.1605G>C (p.Met535Ile)SNV Likely pathogenic 376163 rs1057519800 10:123258076-123258076 10:121498562-121498562
16 FGFR2 NM_000141.5(FGFR2):c.1605G>A (p.Met535Ile)SNV Likely pathogenic 376164 rs1057519800 10:123258076-123258076 10:121498562-121498562
17 PIK3R2 NM_005027.4(PIK3R2):c.1681A>G (p.Asn561Asp)SNV Likely pathogenic 376165 rs1057519801 19:18278061-18278061 19:18167251-18167251
18 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys)SNV Uncertain significance 13983 rs121434592 14:105246551-105246551 14:104780214-104780214

Cosmic variations for Endometrial Adenocarcinoma:

9 (show top 50) (show all 13016)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264503 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 12
2 COSM88264271 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 12
3 COSM88264495 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 12
4 COSM149332944 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 12
5 COSM149265473 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8512G>A p.V2838I 16:72794170-72794170 12
6 COSM149320029 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 12
7 COSM149276742 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1753G>A p.G585S 16:72958393-72958393 12
8 COSM149319798 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 12
9 COSM149259590 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1936G>A p.D646N 16:72958210-72958210 12
10 COSM149286811 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 12
11 COSM149314151 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 12
12 COSM149261368 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4342C>A p.L1448I 16:72798340-72798340 12
13 COSM149284453 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4653G>T p.K1551N 16:72798029-72798029 12
14 COSM149265910 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 12
15 COSM149292038 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8633C>T p.A2878V 16:72794049-72794049 12
16 COSM149293431 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 12
17 COSM149281700 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8617G>A p.E2873K 16:72794065-72794065 12
18 COSM149322559 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2861C>T p.T954M 16:72950824-72950824 12
19 COSM149264593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.629G>A p.G210D 16:72959517-72959517 12
20 COSM149261344 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 12
21 COSM149280950 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2770T>G p.S924A 16:72950915-72950915 12
22 COSM149296225 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 12
23 COSM149293444 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6906G>T p.E2302D 16:72795776-72795776 12
24 COSM149298176 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2119G>A p.G707R 16:72958027-72958027 12
25 COSM149289617 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6965G>A p.R2322Q 16:72795717-72795717 12
26 COSM149293449 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.710G>A p.R237Q 16:72959436-72959436 12
27 COSM149293438 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6935G>A p.R2312Q 16:72795747-72795747 12
28 COSM149297062 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 12
29 COSM149313577 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 12
30 COSM149261333 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 12
31 COSM149320045 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2459G>A p.R820H 16:72957687-72957687 12
32 COSM149321526 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1031A>C p.N344T 16:72959115-72959115 12
33 COSM149290487 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2919G>T p.E973D 16:72950766-72950766 12
34 COSM149320020 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 12
35 COSM149278018 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 12
36 COSM149270196 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 12
37 COSM149302952 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 12
38 COSM149323327 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6881G>A p.R2294Q 16:72795801-72795801 12
39 COSM149281672 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6751G>A p.D2251N 16:72795931-72795931 12
40 COSM149272466 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7882G>A p.E2628K 16:72794800-72794800 12
41 COSM149283769 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 12
42 COSM149325401 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 12
43 COSM149308919 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4315C>T p.R1439* 16:72798367-72798367 12
44 COSM149262204 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 12
45 COSM149272477 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 12
46 COSM149282136 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8029G>A p.E2677K 16:72794653-72794653 12
47 COSM149302940 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 12
48 COSM149281678 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5650G>T p.E1884* 16:72797032-72797032 12
49 COSM149290480 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4072T>G p.S1358A 16:72798610-72798610 12
50 COSM149265665 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 12

Expression for Endometrial Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Adenocarcinoma.

Pathways for Endometrial Adenocarcinoma

Pathways related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 VEGFA TP53 PTEN PGR MLH1 ESR2
2
Show member pathways
13.81 VEGFA TP53 PTEN KRAS FGFR2 ESR2
3
Show member pathways
13.72 VEGFA TP53 KRAS FGFR2 ESR2 ESR1
4
Show member pathways
13.29 VEGFA KRAS FGFR2 ESR2 ESR1 ERBB2
5
Show member pathways
12.99 VEGFA TP53 PTEN KRAS FGFR2 ERBB2
6
Show member pathways
12.81 VEGFA TP53 PTEN MLH1 KRAS FGFR2
7 12.79 VEGFA TP53 KRAS FGFR2 ERBB2 EGFR
8
Show member pathways
12.75 VEGFA KRAS FGFR2 EGFR CDH1
9
Show member pathways
12.74 TP53 PTEN KRAS FGFR2 ERBB2 EGFR
10
Show member pathways
12.72 TP53 PTEN KRAS ESR1 ERBB2 CDH1
11
Show member pathways
12.68 VEGFA PGR KRAS ESR2 ESR1 EGFR
12
Show member pathways
12.59 VEGFA TP53 PTEN KRAS FGFR2 ERBB2
13
Show member pathways
12.52 TP53 PTEN KRAS FGFR2 ERBB2 EGFR
14
Show member pathways
12.51 PTEN KRAS ESR2 ESR1 ERBB2
15
Show member pathways
12.47 TP53 KRAS FGFR2 ERBB2 EGFR
16
Show member pathways
12.47 VEGFA TP53 PTEN KRAS FGFR2 EGFR
17 12.47 VEGFA TP53 PTEN MIR34A MIR200A KRAS
18 12.46 VEGFA TP53 PTEN MLH1 KRAS FGFR2
19
Show member pathways
12.45 TP53 PTEN KRAS FGFR2 ESR2 ESR1
20
Show member pathways
12.41 KRAS FGFR2 ERBB2 EGFR CDH1
21 12.36 TP53 PTEN KRAS CDKN2A
22
Show member pathways
12.34 ESR2 ESR1 ERBB2 EGFR
23
Show member pathways
12.33 TP53 PTEN ERBB2 EGFR
24
Show member pathways
12.33 KRAS ERBB2 EGFR CDH1
25
Show member pathways
12.32 VEGFA TP53 KRAS EGFR
26 12.3 VEGFA TP53 KRAS ESR1 ERBB2 EGFR
27
Show member pathways
12.25 TP53 PTEN KRAS FGFR2 ERBB2 EGFR
28 12.2 PTEN KRAS ERBB2 EGFR
29 12.18 TP53 PTEN KRAS CDKN2A
30 12.17 VEGFA TP53 MLH1 KRAS EGFR CDH1
31
Show member pathways
12.16 PTEN KRAS ERBB2 EGFR
32 12.16 VEGFA TP53 PTEN KRAS ESR1 EGFR
33 12.09 TP53 PTEN MLH1 EGFR
34
Show member pathways
12.07 TP53 PTEN PGR MLH1 KRAS FGFR2
35 12.01 TP53 PTEN KRAS ERBB2 CDKN2A
36 11.98 TP53 PTEN KRAS EGFR CDKN2A
37
Show member pathways
11.96 PGR KRAS ESR1 ERBB2 EGFR
38
Show member pathways
11.9 VEGFA ESR1 ERBB2 EGFR
39 11.76 TP53 MLH1 ERBB2 CDKN2A
40 11.75 ERBB2 EGFR CDH1
41
Show member pathways
11.73 VEGFA ESR1 EGFR
42 11.73 TP53 PTEN KRAS FGFR2 ERBB2 EGFR
43 11.71 TP53 PTEN ERBB2
44 11.66 VEGFA TP53 KRAS ERBB2 EGFR CDKN2A
45 11.63 KRAS ERBB2 EGFR
46 11.61 VEGFA TP53 CDKN2A
47 11.57 TP53 EGFR CDKN2A
48 11.55 VEGFA KRAS ESR1 EGFR
49 11.51 FGFR2 ERBB2 EGFR
50 11.49 VEGFA KRAS FGFR2 EGFR

GO Terms for Endometrial Adenocarcinoma

Biological processes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 VEGFA TP53 PGR FGFR2 ESR1 EGFR
2 positive regulation of transcription, DNA-templated GO:0045893 9.97 TP53 ESR2 ESR1 EGFR CDKN2A CDH1
3 positive regulation of cell proliferation GO:0008284 9.93 VEGFA PTEN KRAS FGFR2 ERBB2 EGFR
4 positive regulation of protein phosphorylation GO:0001934 9.88 VEGFA KRAS ERBB2 EGFR
5 positive regulation of protein kinase B signaling GO:0051897 9.84 FGFR2 ESR1 ERBB2 EGFR
6 transcription initiation from RNA polymerase II promoter GO:0006367 9.83 PTEN PGR ESR2 ESR1
7 regulation of protein stability GO:0031647 9.8 PTEN KRAS CDKN2A
8 positive regulation of kinase activity GO:0033674 9.78 FGFR2 ERBB2 EGFR
9 negative regulation of cell migration GO:0030336 9.78 PTEN MIR34A MIR204 CDH1
10 Ras protein signal transduction GO:0007265 9.77 TP53 KRAS CDKN2A
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.76 PTEN MIR193A CDKN2A
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 EGFR
13 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.62 TP53 ESR1
14 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.61 TP53 ESR1
15 regulation of ERK1 and ERK2 cascade GO:0070372 9.58 FGFR2 ERBB2 EGFR
16 negative regulation of ERBB signaling pathway GO:1901185 9.57 ERBB2 EGFR
17 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 VEGFA TP53
18 positive regulation of epithelial cell proliferation GO:0050679 9.56 VEGFA FGFR2 ERBB2 EGFR
19 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.55 FGFR2 ESR1
20 positive regulation of cellular senescence GO:2000774 9.54 MIR34A KRAS CDKN2A
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.51 ERBB2 CDKN2A
22 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.5 TP53 PTEN MIR34A
23 positive regulation of gene expression GO:0010628 9.5 VEGFA TP53 PTEN MIR34A KRAS ERBB2
24 positive regulation of MAP kinase activity GO:0043406 9.46 VEGFA KRAS ERBB2 EGFR
25 prostate epithelial cord elongation GO:0060523 9.43 FGFR2 ESR1
26 cellular response to hypoxia GO:0071456 9.02 VEGFA TP53 PTEN MIR34A MALAT1

Molecular functions related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.89 TP53 PTEN ESR1 EGFR CDKN2A
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 FGFR2 ERBB2 EGFR
3 steroid hormone receptor activity GO:0003707 9.61 PGR ESR2 ESR1
4 identical protein binding GO:0042802 9.61 VEGFA TP53 PTEN PGR ESR2 ESR1
5 repressing transcription factor binding GO:0070491 9.58 PGR ESR2 ESR1
6 nuclear receptor activity GO:0004879 9.5 PGR ESR2 ESR1
7 nitric-oxide synthase regulator activity GO:0030235 9.48 ESR1 EGFR
8 estrogen receptor activity GO:0030284 9.37 ESR2 ESR1
9 steroid binding GO:0005496 9.33 PGR ESR2 ESR1
10 estrogen response element binding GO:0034056 9.26 ESR2 ESR1
11 enzyme binding GO:0019899 9.17 TP53 PTEN PGR MLH1 ESR2 ESR1

Sources for Endometrial Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....